MarketCap
Facebook
X
TelegramQuarterly report 2026-Q1
added 05-15-2026
ENDRA Life Sciences Interest Expense 2011-2026 | NDRA
Interest expense is the amount of interest a company is obligated to pay to creditors for using debt financing (bank loans, bonds, leasing, etc.) during the reporting period.Includes:
- Interest on bank loans
- Interest on corporate bonds
- Interest on leases
- Interest on credit lines and overdrafts
High interest expenses indicate a high debt burden — the company may be vulnerable to rising rates or declining revenue.
Low interest expenses with high profits are a sign of financial stability.
Annual Interest Expense ENDRA Life Sciences
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | -691 K | 460 K | -21.5 K | -41.5 K | 8.84 K | -107 K | -48 K | 42.6 K | 72 K | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 460 K | -691 K | -36.1 K |
Quarterly Interest Expense ENDRA Life Sciences
| 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | 42 K | 13.1 K | 24.4 K | - | 65.5 K | 1.7 K | -4.84 K | - | 28.2 K | - | - | - | - | - | - | - | -7.51 K | 1.09 K | -2.04 K | - | -2.62 K | 1.26 K | 6.62 K | - | -44.6 K | -9.2 K | -1.52 K | - | -25.5 K | -23.7 K | 12.3 K | - | 2.03 K | 374 K | 28.1 K | - | 373 K | 235 K | -6.02 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 374 K | -44.6 K | 43.2 K |
Interest Expense of other stocks in the Diagnostics research industry
| Issuer | Interest Expense | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Enzo Biochem
ENZ
|
494 K | - | -8.98 % | $ 14.8 K |  USA |
 |
Centogene N.V.
CNTG
|
8.42 M | - | -6.23 % | $ 30.6 M |  Germany |
 |
Heska Corporation
HSKA
|
4.19 M | - | - | $ 1.31 B | USA |
 |
DermTech
DMTK
|
-355 K | - | -11.32 % | $ 2.94 M | USA |
 |
Quest Diagnostics Incorporated
DGX
|
26 M | $ 197.76 | -1.61 % | $ 22 B | USA |
 |
Celcuity
CELC
|
5.33 M | $ 88.05 | 0.84 % | $ 4.12 B | USA |
|
Akumin
AKU
|
118 M | - | -17.87 % | $ 25.9 M |  Canada |
 |
Co-Diagnostics
CODX
|
106 K | $ 3.33 | -13.28 % | $ 4.43 M | USA |
 |
Fulgent Genetics
FLGT
|
153 K | $ 17.7 | -1.61 % | $ 545 M | USA |
 |
Castle Biosciences
CSTL
|
144 K | $ 20.25 | -1.03 % | $ 587 M | USA |
 |
Aspira Women's Health
AWH
|
1.81 M | - | -6.19 % | $ 10.5 M | USA |
 |
Accelerate Diagnostics
AXDX
|
-595 K | - | -61.36 % | $ 2.46 M | USA |
 |
Guardant Health
GH
|
-10.5 M | $ 129.11 | 1.39 % | $ 16.2 B | USA |
 |
Biocept
BIOC
|
316 K | - | -13.05 % | $ 7.29 M | USA |
 |
Interpace Biosciences
IDXG
|
-394 K | $ 1.65 | 4.78 % | $ 7.3 M | USA |
 |
CareDx, Inc
CDNA
|
524 K | $ 23.48 | 0.99 % | $ 1.25 B | USA |
 |
Chembio Diagnostics
CEMI
|
2.94 K | - | 0.22 % | $ 16.8 M | USA |
 |
Illumina
ILMN
|
340 M | $ 159.09 | -3.16 % | $ 24.7 B | USA |
 |
Check-Cap Ltd.
CHEK
|
13 K | - | - | $ 9.42 M |  Israel |
 |
ICON Public Limited Company
ICLR
|
337 M | $ 143.27 | -0.19 % | $ 11.2 B |  Irlanda |
 |
HTG Molecular Diagnostics
HTGM
|
857 K | - | -20.0 % | $ 1.06 M | USA |
 |
Global Cord Blood Corporation
CO
|
6.27 M | - | - | $ 399 M |  China |
 |
Genetic Technologies Limited
GENE
|
17.6 K | - | - | $ 7.1 B |  Australia |
 |
National Research Corporation
NRC
|
-95 K | $ 17.75 | -3.9 % | $ 397 M | USA |
 |
Lantheus Holdings
LNTH
|
31.3 M | $ 103.19 | -1.75 % | $ 6.96 B | USA |
 |
Natera
NTRA
|
4.07 M | $ 226.44 | 2.88 % | $ 31 B | USA |
 |
Charles River Laboratories International
CRL
|
-22.6 M | $ 182.34 | -1.33 % | $ 9.04 B | USA |
 |
Pacific Biosciences of California
PACB
|
14.8 M | $ 1.34 | -0.74 % | $ 402 M | USA |
 |
Medpace Holdings
MEDP
|
-5.34 M | $ 457.09 | -0.98 % | $ 13.2 B | USA |
 |
Mettler-Toledo International
MTD
|
68.5 M | $ 1 129.53 | -1.91 % | $ 23.3 B |  Schweiz |
 |
Exact Sciences Corporation
EXAS
|
18.6 M | - | - | $ 19.8 B | USA |
 |
NeoGenomics
NEO
|
296 K | $ 10.38 | -1.05 % | $ 1.33 B | USA |
 |
Myriad Genetics
MYGN
|
800 K | $ 4.38 | 3.06 % | $ 406 M | USA |
 |
Personalis
PSNL
|
205 K | $ 9.75 | 0.62 % | $ 870 M | USA |
 |
Koninklijke Philips N.V.
PHG
|
288 M | $ 26.24 | -2.09 % | $ 24.9 B |  Niderland |
 |
Senseonics Holdings
SENS
|
-23 K | $ 6.69 | -7.47 % | $ 279 M | USA |
 |
QIAGEN N.V.
QGEN
|
-6.65 M | - | - | $ 10.6 B | Niderland |
 |
Soleno Therapeutics
SLNO
|
2.58 M | - | - | $ 2.69 B | USA |
 |
Biomerica
BMRA
|
367 | $ 1.97 | 2.07 % | $ 4.53 M | USA |
 |
Twist Bioscience Corporation
TWST
|
-903 K | $ 82.87 | -2.45 % | $ 4.96 B | USA |
 |
Laboratory Corporation of America Holdings
LH
|
224 M | $ 259.56 | -2.03 % | $ 21.6 B | USA |
 |
Thermo Fisher Scientific
TMO
|
-12 M | $ 461.69 | -2.31 % | $ 174 B | USA |
 |
Trinity Biotech plc
TRIB
|
6.75 M | $ 0.58 | 1.74 % | $ 208 M | Irlanda |
 |
Motus GI Holdings
MOTS
|
211 | - | -34.28 % | $ 263 K | Israel |
 |
Neogen Corporation
NEOG
|
38.1 M | $ 8.93 | -4.08 % | $ 1.94 B | USA |
 |
Invitae Corporation
NVTA
|
56.7 M | - | - | $ 21.2 M | USA |